Interview with Japan Chemical Daily
Cellular Therapy for Knee OA
Mr. John Martin, CEO of the Australian regenerative medicine venture company, Regeneus, agreed to be interviewed by this newspaper and relayed his plan to locate an out-license partner for the firm’s Knee Osteoarthritis (OA) cellular therapy. Progenza is garnering interest from a number of companies on the back of Regeneus’ Australian Phase I data, which showed possible disease modifying properties. AGC Asahi Glass already has exclusive manufacturing rights for Progenza in Japan.